Clinical trial entrants include projects from Gyala, Beijing Biotech and Neowise.
ApexOnco Front Page
Recent articles
Pivotal trials of sonrotoclax plus the group’s BTK degrader are set to start soon.
The private ADC company is being wound down.
In fit KMT2Ar patients the group will focus on Revuforj plus Venclexta and azacitidine.
Two new PD-(L)1 x VEGF projects have entered the clinic.
Ideate-Lung02 goes on global clinical hold.
The new phase 3 trial, in first-line CLL, is expected to begin in January 2026.
Astra and Daiichi bag FDA approval based on Destiny-Breast09.
